Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood pressure drug ease chest pain in people with clear arteries?

NCT ID NCT07670091

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether bosentan, a drug that blocks a natural vessel-constricting substance, can improve blood flow in the tiny heart vessels of people with angina who have no major blockages. About 45 participants will get bosentan for 4 weeks and have MRI scans before and after. The goal is to understand if this approach could lead to new treatments for microvascular angina.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bosentan (endothelin receptor antagonist)
What this could lead to
If it works, this could point toward a new treatment for angina caused by small vessel problems, not just blocked arteries.
What could go wrong
This is a very small, early study (45 people) looking at blood flow changes, not symptoms. Bosentan may not improve angina or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinical diagnosis of symptomatic angina, defined as the presence of substernal chest pain or discomfort provoked by exertion or emotional stress and relieved by rest and/or glyceryl trinitrate (nitroglycerin). 2. Age 18 years or older. 3. Able and willing to provide written informed consent. 4. Able and willing to adhere to study procedures and follow-up requirements. Exclusion Criteria: 1. Symptoms consistent with unstable angina, including: 2. Angina at rest lasting more than 20 minutes. 3. New-onset severe angina. 4. Angina increasing in frequency, duration, or occurring at a lower threshold. 5. Angina occurring following a recent myocardial infarction. 6. Known significant coronary artery disease, defined as previous investigations demonstrating greater than 50% epicardial coronary artery stenosis. 7. Uncontrolled hypertension, defined as clinic blood pressure greater than 140/90 mmHg despite treatment with three or more antihypertensive medications. 8. Pregnancy or breastfeeding. 9. Poorly controlled asthma as defined in the study protocol. 10. Severe heart failure or symptoms of active heart failure. 11. Significant chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m². 12. Clinical evidence of active infection at the time of recruitment. 13. Significant liver disease, defined as Child-Pugh Class B or C liver disease (or worse than Child-Pugh Class A). 14. Systolic blood pressure less than 90 mmHg at the time of recruitment. 15. Previously documented allergy or hypersensitivity to endothelin receptor antagonists. 16. Concurrent use of medications contraindicated with endothelin receptor antagonist therapy. 17. Requirement for invasive coronary angiography for another clinical indication, including but not limited to valvular heart disease assessment or intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina pectoris with normal coronary arteriogram are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NHS University Hospitals of Liverpool Group

    Liverpool, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.